Ombudsman disagrees with EMA clinical trial data disclosure policy
This article was originally published in SRA
Executive Summary
The European Ombudsman has criticised the European Medicines Agency for turning down requests for access to certain clinical trial data on two anti-obesity drugs – orlistat and rimonabant – on the grounds of protecting drug company commercial interests1,2.